Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 1/20 | 0.32 |
| ▸ | EGFR | P00533 | 2/20 | 0.32 |
| ▸ | LCK | P06239 | 1/20 | 0.32 |
| ▸ | JAK3 | P52333 | 1/20 | 0.32 |
| ▸ | BTK | Q06187 | 1/20 | 0.32 |
| ▸ | ITK | Q08881 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16701713 | 0.94 | EGFR (0.33) | F10EGFRLCKJAK3BTK | |
| SCHEMBL16702107 | 0.92 | EGFR (0.33) | F10EGFRLCKJAK3BTK | |
| SCHEMBL16701774 | 0.92 | F10 (0.32) | F10EGFRLCKJAK3BTK | |
| SCHEMBL16701648 | 0.92 | F10 (0.36) | F10EGFRLCKJAK3BTK | |
| SCHEMBL16701574 | 0.92 | F10 (0.32) | F10EGFRLCKJAK3BTK | |
| SCHEMBL16701631 | 0.90 | EGFR (0.34) | EGFRLCKJAK3BTKITK | |
| SCHEMBL16701781 | 0.89 | F10 (0.32) | F10EGFRLCKJAK3BTK | |
| SCHEMBL16701427 | 0.89 | EGFR (0.38) | F10EGFRLCKJAK3BTK | |
| SCHEMBL16702450 | 0.89 | SRC (0.34) | F10EGFRLCKJAK3BTK | |
| SCHEMBL16701753 | 0.88 | F10 (0.32) | F10EGFRLCKJAK3BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160272645-A1 | Heterocyclic Compounds and Methods of Use | MEDIVATION TECHNOLOGIES, INC. (US) | 2016-09-22 | — | — | US | claimed |
| WO-2015069441-A1 | PYRAZOLO-, IMIDAZOLO- AND PYRROLO-PYRIDINE OR -PYRIMIDINE DERIVATIVES AS INHIBITORS O BRUTONS KINASE (BTK) | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-05-14 | — | — | WO | claimed |
| US-20160272645-A1 | Heterocyclic Compounds and Methods of Use | MEDIVATION TECHNOLOGIES, INC. (US) | 2016-09-22 | — | — | US | disclosed |
| US-20160272645-A1 | Heterocyclic Compounds and Methods of Use | MEDIVATION TECHNOLOGIES, INC. (US) | 2016-09-22 | — | — | US | disclosed |
| WO-2015069441-A1 | PYRAZOLO-, IMIDAZOLO- AND PYRROLO-PYRIDINE OR -PYRIMIDINE DERIVATIVES AS INHIBITORS O BRUTONS KINASE (BTK) | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160272645-A1 | Heterocyclic Compounds and Methods of Use | BTK, PIK3CD, PIK3CB | F10 3348/4885EGFR 828/4885LCK 51/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.